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Abstract: Background: Readiness for smoking cessation is an important predictor of quit
attempts and cessation success. We aimed to investigate the prevalence and
correlates of readiness for smoking cessation in coronary heart disease (CHD)
patients.
Design: The EUROASPIRE III survey is a cross-sectional study conducted in 2006-
2007 among CHD patients <80 years of age from 22 European regions.
Methods: Patients were interviewed on average 15 months after hospital admission for
an acute coronary event or procedure. Readiness for smoking cessation was assessed
using the smoking stages of change (SSC) short form questionnaire. Breath carbon
monoxide was measured to validate self-reported non-smoking.
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Results: Among 2,585 patients who were smoking prior to hospital admission, 25.6%,
16.8%, 8.1%, 5.6% and 44.0% were in the precontemplation (no intention to quit),
contemplation (thinking of quitting), preparation (planning to quit), action (having quit
within 6 months) and maintenance (having quit more than 6 months ago) stage,
respectively. Significant multivariable correlates of advancement in SSC showed
positive associations of older age and attended cardiac rehabilitation and negative
associations of severe depressive symptoms, longer smoking duration and
environmental tobacco smoke (ETS) exposure.
Conclusions: One quarter of CHD patients across Europe who were smoking prior to
hospitalisation have no intention to quit, and an additional quarter is thinking of quitting
or planning to quit. Patients who are younger, do not attend cardiac rehabilitation, have
severe depressive symptoms, have been smoking for longer periods of time and are
exposed to ETS may need to be specifically targeted in cessation interventions.
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Dear Prof. Grobbee, 
 
On behalf of my co-authors I would like to submit the revised version of our manuscript entitled “Readiness 
for smoking cessation in coronary heart disease patients across Europe: results from the EUROASPIRE III 
survey” for further consideration by European Journal of Preventive Cardiology. 
 
Our study is set against the background that readiness for smoking cessation is a strong predictor of quit 
attempts and cessation success and that about half of coronary heart disease patients across Europe continue 
smoking after hospitalisation for an acute coronary event or procedure. 
 
The valuable comments and suggestions of the reviewers have enabled us to improve the readability of the 
manuscript and to complement the reported results. Briefly, we have (a) described smoking stages of change 
(SSC) in table format, (b) added a table on SSC with stratification by sex, (c) provided a supplementary table 
on SSC by geographical regions and (d) added descriptive data in a total of three tables. 
 
In our view, the revised manuscript underlines the low readiness for smoking cessation in coronary patients 
who were smoking prior to hospitalisation across Europe and emphasises patient groups that may need to be 
specifically targeted in cessation interventions. 
 
We hope you will find our work suitable for publication and are looking forward to hearing from you. 
 
Thank you for considering our work. 
 
Yours sincerely, 
 
 
Christof Prugger, MD, MSc 
 
INSERM, U970, Paris Cardiovascular Research Centre 
University Paris Descartes, Sorbonne Paris Cité 
Georges Pompidou European Hospital 
56 rue Leblanc, 75015 Paris, France 
Tel: +33 1 53 98 79 60; Fax: +33 1 53 98 79 54 
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Response to the editor and reviewers 
 
We thank the editor for his efforts in handling the manuscript and the reviewers for 
their valuable comments and suggestions. An itemised response to the reviewers is provided 
below indicating the changes made in the manuscript. These were implemented using the 
‘track-changes’ option in the text and highlighted in yellow within the tables. As one further 
relevant paper that was recently published in the journal, the work by Perk et al. Eur J Prev 
Cardiol 2012; 19:585-667 was included in the reference list. 
The revision comprises, among others, the inclusion of two additional tables reducing 
the maximum number of word to 3,750. This was accommodated by editing and shortening 
the text, the references in particular. The final word count is 3,871 and thus exceeds the limit 
by 121 words. We feel that further text shortening would adversely affect the quality of the 
paper. Nevertheless, we are ready to abridge the manuscript, should this prove necessary. 
 
Reviewer #1: 
 
This article addresses a very important issue by not only showing the context of smoking 
cessation challenges but also providing a number of simple and straightforward solutions to 
help patients increase their success rate of quitting. 
 
1.1 What I missed was a break down per country or even region. I would be interested to 
know if there were differences that need to be dealt with differently in those geographical 
areas. 
 
Following the reviewer’s comment, an additional table (Supplementary Table 1) was included 
showing the smoking stages of change by geographical regions. Please note that the rather 
Response to review
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small number of patients by region precluded us form conducting statistical analyses in these 
sub-samples. 
 
1.2 The readability of the paper could be improved by adding some more structured 
information like bullet points, graphs, and boxes with major conclusions as well as simple 
advice for clinicians with simple steps to follow in order to improve smoking cessation rates. 
 
In order to improve the readability of the paper, we implemented the following changes. First, 
the description of smoking stages of change was included in a structured table format (Table 
1), which was also suggested by reviewer #2. Second, regarding simple advices for clinicians, 
the heading ‘Current evidence on smoking cessation interventions’ was inserted to emphasize 
more clearly the discussion section on page 15 and 16 dealing with this issue. Further, in this 
section, the interventions and results of one recent randomised controlled trial among high 
risk smokers were outlined in more detail. Third, with regard to major conclusions, we would 
like to draw the attention of the reviewer to the section at the end of the discussion section on 
page 19. To highlight these conclusions, we now introduce this section by the statement: ‘As 
major conclusions of our study we would like to note the following.’ 
 
Reviewer #2: 
 
The study assessed the level of readiness for smoking cessation among a sample of 2585 
smoking coronary heart disease (CHD) patients in 76 clinical centers representing 22 
European regions (Euroaspire III survey).  Readiness for smoking cessation was assessed by 
using the smoking stages of change (SSC) questionnaire.  The aims of the study were: (1) to 
describe the distribution of SSC, and (2) to investigate correlates of advancement in SSC 
among CHD patients who were smoking prior to hospital admission for a coronary event or 
3 
procedure. Smoking is one of the main risk factors for CHD, and cessation of smoking is 
particularly important for people having high level of other cardiovascular risk factors or 
existing cardiovascular disease. Therefore, the study questions are both scientifically and 
clinically important. The study is conducted by using appropriate methodology and the report 
is well written. However, the reviewer would like to suggest the following minor changes: 
 
2.1 Page 8: Kindly provide the description of different SSC levels in table format instead 
of verbal description in the text. 
 
The description was provided as requested in the added Table 1. 
 
2.2 Even though sex was not associated with advancement in SSC it would be useful to 
provide some background information by sex. Descriptive data on page 12 could be provided 
in a table stratified by sex (men, women, total). 
 
The requested data were provided in the added Table 2. In order to avoid duplicate 
information, SSC by sex was deleted from the Figure and Supplementary Table 2. 
 
2.3 Add to table 1 and 2 the number of patients in each category.   
 
These numbers were included in the tables (now Table 3 and 4). 
 
2.4 If possible, the supplementary table could be included to the main text. 
 
4 
Unfortunately, no supplementary table could be included in the main text because of the 
limited word count (please see above). In line with the comment on table 1 and 2, numbers 
were added in each category to supplementary table 2 (now Supplementary Table 3). 
 
2.5 Supplementary data on SSC distribution by different regions would be interesting even 
though the number of patients in some regions may be too small for statistical analysis. 
 
Data on SSC distribution by geographical regions were provided as Supplementary Table 1. 
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Abstract 
Background: Readiness for smoking cessation is an important predictor of quit attempts 
and cessation success. We aimed to investigate the prevalence and correlates of 
readiness for smoking cessation in coronary heart disease (CHD) patients. 
Design: The EUROASPIRE III survey is a cross-sectional study conducted in 2006–
2007 among CHD patients <80 years of age from 22 European regions. 
Methods: Patients were interviewed on average 15 months after hospital admission for 
an acute coronary event or procedure. Readiness for smoking cessation was assessed 
using the smoking stages of change (SSC) short form questionnaire. Breath carbon 
monoxide was measured to validate self-reported non-smoking. 
Results: Among 2,585 patients who were smoking prior to hospital admission, 25.6%, 
16.8%, 8.1%, 5.6% and 44.0% were in the precontemplation (no intention to quit), 
contemplation (thinking of quitting), preparation (planning to quit), action (having quit 
within 6 months) and maintenance (having quit more than 6 months ago) stage, 
respectively. Significant multivariable correlates of advancement in SSC showed 
positive associations of older age and attended cardiac rehabilitation and negative 
associations of severe depressive symptoms, longer smoking duration and 
environmental tobacco smoke (ETS) exposure. 
Conclusions: One quarter of CHD patients across Europe who were smoking prior to 
hospitalisation have no intention to quit, and an additional quarter is thinking of quitting 
4 
or planning to quit. Patients who are younger, do not attend cardiac rehabilitation, have 
severe depressive symptoms, have been smoking for longer periods of time and are 
exposed to ETS may need to be specifically targeted in cessation interventions. 
 
Abstract word count: 250 
5 
Keywords 
stages of change; smoking cessation; coronary artery disease; epidemiology 
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Introduction 
Smoking cessation is the most effective measure of secondary prevention in 
patients with coronary heart disease (CHD) substantially reducing cardiovascular 
morbidity and mortality.
1,2
 Current data, however, show that about half of smokers who 
suffer an acute coronary event or undergo coronary revascularisation across Europe 
continue smoking after hospitalisation.
3
 
Existing evidence for the treatment of tobacco use suggests that patients who are 
ready to change their problem behaviour achieve higher smoking abstinence rates.
4
 
Readiness for smoking cessation is most commonly assessed using the smoking stages 
of change (SSC) of the transtheoretical model (TTM). The SSC comprise the 
precontemplation (no intention to quit), contemplation (thinking of quitting), 
preparation (planning to quit), action (having quit within 6 months) and maintenance 
(having quit more than 6 months ago) stage.
5
 According to the TTM, smokers advance 
through these stages of self-change before they quit successfully, whilst relapse to lower 
stages is possible.
6,7
 
Investigating the distribution and correlates of SSC in CHD patients may 
provide important insights into the motivational readiness for smoking cessation and 
enable identifying patient groups that need to be specifically targeted in cessation 
interventions. However, data on SSC in CHD patients are currently scarce, and no prior 
multicentre study has reported on SSC in this high risk group. EUROASPIRE 
7 
(EUROpean Action on Secondary and Primary Prevention through Intervention to 
Reduce Events) comprises a series of multicentre studies across Europe to evaluate 
primary and secondary prevention of cardiovascular disease, offering the opportunity to 
address these outstanding issues in a sample of European CHD patients. 
The objectives of the present study were, firstly, to describe the distribution of 
SSC and, secondly, to investigate correlates of advancement in SSC among CHD 
patients who were smoking prior to hospital admission for a coronary event or 
procedure. 
Methods 
Study participants 
The EUROASPIRE III survey among CHD patients is a cross-sectional study 
conducted in 2006–2007. Details of the study design and participant recruitment have 
been described elsewhere.
78
 Patients hospitalised for coronary artery bypass graft 
(CABG), percutaneous coronary intervention (PCI), acute myocardial infarction (AMI) 
and myocardial ischemia were retrospectively identified from hospital records at 76 
centres in 22 European regions. Trained research staff reviewed 13,935 medical records 
and interviewed 8,966 patients up to 80 years of age at least 6 months after 
hospitalisation for the index event or procedure. Among these patients, a total of 2,723 
(30.4%) reported at interview that they were smoking in the month prior to their 
hospital admission. 
8 
Information on study centres and organisations is provided as Supplementary 
Material. The study complies with the Declaration of Helsinki and was approved by, 
local ethics committees have approved the research protocol., and i Informed consent 
has beenwas obtained from study participants. 
Smoking stages of change 
SSC were assessed in a face-to-face interview using the short form 
questionnaire: ‘Do you smoke now?’ and if not smoking, ‘Did you quit within the last 6 
months/more than 6 months ago?’, whereas if smoking ‘In the last year, how many 
times have you quit smoking for at least 24 hours?’ and ‘Are you seriously thinking of 
quitting smoking?’. Possible answers to the latter question were: ‘Yes, within the next 
30 days’, ‘Yes, within the next 6 months’, ‘No, not thinking of quitting’ and ‘Don’t 
know/Unsure’. SSC were defined as described in Table 1. According to the TTM, the 
maintenance stage and action stage were defined as having quit more than 6 months ago 
and within the last 6 months, respectively; the preparation stage was defined as thinking 
of quitting within the next 30 days and having at least one 24-hour quit attempt in the 
past year; the contemplation stage was defined as thinking of quitting within the next 6 
months or within the next 30 days without a 24-hour quit attempt in the past year; the 
precontemplation stage was defined as not thinking/being unsure of quitting. 
Carbon monoxide in breath 
9 
Carbon monoxide (CO) in breath was measured for biochemical validation of 
self-reported non-smoking at interview. The concentration of breath CO was recorded in 
parts per million (ppm) using calibrated instruments and following the manufacturer’s 
specifications (Bedfont Scientific, Model Micro 4 Smokerlyser, Bedfont Scientific, Kent, 
UK). After a 15-second breath hold, participants were asked to breathe out steadily and 
gently through a disposable mouthpiece connected to the monitor, emptying the lungs as 
much as possible. Following each CO measurement, the system was cleared for the next 
procedure exposing the sensor to room air. Self-reported non-smoking was validated 
using 10 ppm CO in breath as cut-off value. 
Covariates 
We investigated age at event, sex and the following other patient characteristics , 
educational level, diagnostic group, time since hospital admission, recurrent CHD, 
cardiac rehabilitation, Hospital Anxiety and Depression Scale (HADS), smoking 
duration and environmental tobacco smoke (ETS) as covariates of SSC. Four 
eEducational levels were considered were: primary, secondary, intermediate and higher 
education. DPatients were categorised into diagnostic groups were defined according to 
theirpatients’ index event or procedure. Recurrent CHD events were self-reported 
CABG, PCI, AMI or myocardial ischemia since hospital discharge. Information on 
cardiac rehabilitation was assessed at interview using the following questions: ‘Were 
you advised to follow a cardiac prevention/rehabilitation programme within 3 months of 
10 
discharge following the index event or procedure?’ and ‘If yes, did you attend the 
cardiac rehabilitation programme offered?’ We categorised patients who were not 
advised, patients who were advised, but did not attend, and patients who attended 
cardiac rehabilitation. The Hospital Anxiety and Depression Scale (HADS), a 4-point 
Likert scale (range 0–3) with 7 items being related to anxiety and 7 items to depression, 
was administered at interview. Item scores are added to obtain the summary scores on 
anxiety and depression separately. A score <8 is considered to be in the normal range, 
scores from 8 to 10 indicate a presence of moderate anxiety and depressive symptoms 
and a score ≥11 a presence of severe symptoms. Smoking duration was assessed by 
asking the question ‘For how many years in total have you smoked?’ and categorized 
into quartiles. Exposure to environmental tobacco smoke (ETS) was assessed by asking 
the following question at interview: ‘In the daytime or at night, do you frequently stay 
in rooms where people smoke at home, at work and at other locations?’ Participants 
were asked to respond to this question providing separate answers for each location 
(yes/no). We evaluated exposure to ETS at any place by constructeding a composite 
variable that combininged information on exposure at home, at work and at other 
locations. 
Statistical analysis 
Descriptive statistics present patient characteristics and SSC. Associations of 
patient characteristics with advancement in SSC were estimated using a continuation ratio 
11 
model with geographical region modelled as a random effect. The continuation ratio 
model is a logit analysis of variables with ordered categories, appropriate when study 
units need to advance through stageslower categories before higher categories can be 
reacheds.
89
 A continuation ratio model for an outcome variable with k ordered 
categories can be thought of as a combination of k-1 separate logistic regression models. 
For the s
th
 stage, one considers only data from those participants who have reached 
stage s or higher on the SSC scale, in our application, and formulates a logistic 
regression model for achieving stage s+1 or higher, s=1,...,k-1. A simple continuation 
ratio model considers these k-1 models jointly, leading to homogeneous estimates for 
the effects of explanatory variables on the odds of advancement on the SSC scale. This 
is our primary analysis of the SSC outcome, whereby a multivariable model was fitted 
using stepwise backward selection among significant covariates identified in separate 
analyses plus the variable age at eventgroup. In an ‘unconstrained’ model, the effects of 
the explanatory variables may change from stage to stage. This flexibility is formally 
achieved by incorporating appropriate interaction terms into the model, and has been 
performed as secondary analysis in the current study. 
All patients for whom data were available on the variables concerned were 
considered in the descriptive and separate analyses, and only patients with data on all 
covariates entered the multivariable analysis. Statistical tests were two-tailed, and an 
12 
alpha level of 0.05 was chosen to indicate statistical significance. The statistical analysis 
was carried out using SAS software version 9.4 (SAS Institute Inc., Cary, NC).
910
 
Results 
Study population 
In the present study, we included 2,585 patients who were smoking in the month 
prior to hospital admission and who were interviewed a median of 15.2 (interquartile 
range 11.2-21.6) months later. We excluded 60 (2.2%) patients due to missing 
information on SSC and 78 (2.8%) patients who reported non-smoking at interview, but 
who had CO in breath >10 ppm. Patients included were older (mean [SD] 56.5 [9.0] 
years vs. 53.7 [8.7] years, p=0.005) and more educated (higher education 16.4% vs. 
15.3%, p=0.008) than those excluded, but similar with regard to sex and diagnostic 
group. 
Frequency distribution of smoking stages of change 
Overall, 25.6%, 16.8%, 8.1%, 5.6% and 44.0% of patients were in the 
precontemplation, contemplation, preparation, action and maintenance stage, 
respectively (Table 2). No significant difference in SSC was observed between sexes 
(p=0.431). Among the 1,305 patients who were smoking at interview, 50.7%, 33.2% 
and 16.1% respectively were in precontemplation, contemplation and preparation stage. 
SSC by geographical regions are shown in Supplementary Table 1. 
13 
The Figure presents mosaic plots showing the frequency distribution of SSC by 
patient characteristics (please see also Supplementary Table 21). The frequency of 
precontemplation, contemplation, preparation, action and maintenance stage by patient 
characteristics ranged from 18.0% to 38.8%, the frequency of contemplation stage from 
11.7% to 19.8%, the frequency of preparation stage from 5.9% to 12.6%, the frequency 
of action stage from 3.6% to 8.2%, and the frequency of maintenance stage from 32.5% 
to 54.6%, respectively. 
Correlates of advancement in smoking stages of change 
Separate associations of patient characteristics with advancement in SSC are 
shown in Table 31. Significant associations with SSC advancement were observed for 
all investigated covariates, except for age at event, sex, time since hospital admission 
and recurrent CHD. Table 42 presents multivariable associations of patient 
characteristics with advancement in SSC after backward selection. Age at event (70-79 
vs. <50 years, OR 1.92, 95% confidence interval [CI] 1.38-2.66), attended cardiac 
rehabilitation (OR 1.37, 95% CI 1.16-1.63), severe depressive symptoms (OR 0.60, 
95% CI 0.48-0.76), smoking duration (>40 vs. ≤26 years, OR 0.45, 95% CI 0.35-0.56) 
and ETS exposure (OR 0.51, 95% CI 0.44-0.58), but not educational level, diagnostic 
group and HADS anxiety, were significantly associated with advancement in SSC. 
Secondary analysis 
14 
When further evaluating whether these effects were similar at each of the SSC, 
significant interactions of stage were observed with age at event and exposure to ETS 
(P=0.002 for both): older age and ETS exposure were significantly associated with 
advancement from the precontemplation through the action stage, but not from the 
action to the maintenance stage (Supplementary Table 32). 
 
Discussion 
Here, we report on the prevalence and correlates of the readiness for smoking 
cessation among CHD patients from 22 European regions. 
Prevalence of readiness for smoking cessation 
On average 15 months after hospitalisation, only about half of patients had 
stopped smoking within the last 6 months (action stage) or more than 6 months ago 
(maintenance stage), whereas one quarter of patients were not thinking of quitting 
(precontemplation stage) and thinking of quitting/planning to quit within the next 6 
months or 30 days (contemplation and preparation stage), respectively. Among 
persistent smokers at interview, more than half of patients were in precontemplation 
stage, one third was in contemplation stage and one sixth was in preparation stage. 
Conceptualised in the early eighties in the context of studies on substance abuse 
and dependence, the stages of change of the TTM have gained considerable recognition 
in medical research. According to the model theory, smokers should be targeted by 
15 
smoking cessation interventions matched to their level of readiness to quit.
101
 
Prospective evaluation of the TTM showed that individuals in the precontemplation and 
contemplation stage are less frequently inclined to attempt and less likely to achieve 
quitting.
112
 A cross-validation study of the TTM supports the applicability of the SSC to 
the group of cardiac patients.
123
 
The frequency distribution of SSC in general population samples varies between 
studies and settings,
14-19
 but also rather similar pattern of stage distributions have been 
reported across study samples.
20,21
 Interestingly, a positive association has been 
observed between the population prevalence of smoking and the proportion of smokers 
in the precontemplation stage.
1322
 We are not aware of any prior multicentre study that 
investigated the readiness for smoking cessation among CHD patients. The frequency 
distribution of SSC observed in our study gives rise to concern, particularly in light of 
the high cardiovascular risk of CHD patients. Smokers hospitalized for CHD across 
Europe thus need to be targeted more specifically by cessation strategies that may 
include behavioural counselling in conjunction with pharmacotherapy.
23,24
 
Current evidence on smoking cessation interventions 
Among CHD patients, A randomized controlled trials (RCTs) among smokers at 
high cardiovascular risk that compared have shown that case-management and a nurse-
led preventive cardiology programmes based on(offering behavioural interventions 
intensive cessation counselling and optional pharmacological support) with usual care in 
16 
general practice showed a substantially increased smoking cessation abstinence over 16 
weeksrates.
25,1426
 Clinical practice guidelines for treating tobacco use currently 
recommend to offer treatment and counselling to patients willing to quit and to promote 
motivation in unwilling patients.
4
 A meta-analysis of RCTs on stage-based interventions 
based on the TTM for smoking cessation showed no additional benefit of tailoring self-
help measures and individual counselling to SSC.
101
 By contrast, a recent cluster 
randomized trial in basic care units (family physician and nurse who care of the same 
group of patients) in primary care centres comparing a stepped smoking cessation 
intervention with standard cessation advice showed a 50% increased likelihood of 
smoking abstinence in the intervention group after 2 years of follow-up.
1527
 However, 
the efficacy of such smoking cessation intervention needs to be evaluated among CHD 
patients before its application in clinical practice can be advocated. 
Correlates of readiness for smoking cessation 
The continuation ratio model proved well-suited to the TTM of behaviour 
change for the purpose of investigating correlates of the readiness for smoking 
cessation. In multivariable analysis, Wwe identified positive associations of older age 
and attended cardiac rehabilitation and negative associations of severe depressive 
symptoms, longer smoking duration and ETS exposure with advancement in SSC. 
Significant associations of educational level, diagnostic group and HADS anxiety with 
17 
advancement in SSC in separate analyses were attenuated to non-significance in the 
multivariable analysis. 
Various subject characteristics including socio-demographics (age, education, 
income), smoking history (duration, daily cigarettes) and medical conditions (health 
problems, disease symptoms) have been shown to be associated with SSC among study 
volunteers, different patient groups and general population samples.
 16-1928-31
 To the best 
of our knowledge, however, no prior study has evaluated correlates of SSC inamong the 
group of CHD patients. The independent association of age at event, cardiac 
rehabilitation, HADS depression, smoking duration and ETS exposure suggest an 
influential role of these patient characteristics in the readiness for smoking cessation. 
From the current literature it is known that people at older age more frequently quit 
smoking, that patients smokers who suffer from a depressive disorder are less likely to 
stop smoking, that the longer a person smokes, the less probable he or she will refrain 
from tobacco use, and that people are more likely to stop smoking in smoke-free 
environments.
32-35
 A systematic review and meta-analysis of RCTs on the efficacy of 
exercise-based cardiac rehabilitation in CHD patients showed a 36% decreased 
likelihood of persistent smoking after at least 6 months of follow-up.
2036
 Based on data 
from EUROASPIRE we have previously shown that age at event, cardiac rehabilitation, 
HADS depression, smoking duration and ETS exposure are, among others, associated 
with the likelihood of smoking cessation in CHD patients across Europe.
21,2237-39
 Results 
18 
of the present study extend upon these findings by revealing an intermediary effect of 
these patient characteristics in the process of behaviour change via the readiness for 
smoking cessation. Our findings from the secondary analysis indicate a homogenous 
effect size of cardiac rehabilitation, HADS depression and smoking duration across 
SSC. However, the effect of age at event and ETS exposure was confined to the 
advancement from the precontemplation up to the action stage, suggesting that these 
characteristics become less relevant once CHD patients have become tobacco abstinent. 
By investigating correlates of the readiness for smoking cessation, we identified patient 
groups that are more likely to remain in lower SSC and who may thus need to be 
specifically targeted in routine clinical practice. These comprise younger patients, non-
participants in cardiac rehabilitation, patients with severe depressive symptoms, long-
term smokers and patients exposed to ETS. The development of future stage-based 
smoking cessation interventions may benefit from our findings when considering patient 
characteristics that are negatively correlated with advancement in SSC. 
Limitations and strengths 
There are some limitations to the present study. First, due to its cross-sectional 
nature, the dynamic process of the readiness for behaviour change over time could not 
be considered. Furthermore, correlates of SSC were assessed simultaneously with the 
readiness for smoking cessation. Thus, prospective studies of SSC should be conducted 
to confirm the observed associations. Second, the rather small study sample hampered 
19 
conducting analyses by geographical regions. However, pooled data analysis considered 
geographical region as a random effect using multilevel modelling. Third, we lacked 
information on the amount of tobacco smoked per day prior to hospitalisation that may 
have influenced the readiness for smoking cessation. 
Among strengths of our study we would like to note the same study protocol and 
standardised procedures used for the assessment of SSC and investigated covariates in a 
multicentre study design. 
Conclusions 
As major conclusions of our study we would like to note the following. One 
quarter of CHD patients across Europe who were smoking prior to hospital admission 
for a coronary event or procedure have no intention to quit smoking, and an additional 
quarter is thinking of quitting or planning to quit. Patients who belong to younger age 
groups, do not take up cardiac rehabilitation, experience a severe level of depressive 
symptoms, have been smoking for a longer period of time and are exposed to ETS may 
need to be specifically targeted by appropriate smoking cessation interventions.
20 
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Legend for figure 
 
Figure: Mosaic plots showing the frequency distribution of smoking stages of change 
by patient characteristics (N=2,585) 
SSC, smoking stages of change; PCS, precontemplation stage; CS, contemplation stage; 
PS, preparation stage; AS, action stage; MS, maintenance stage. 
Int., intermediate; PCI, percutaneous coronary intervention; CABG, coronary artery 
bypass graft; AMI, acute myocardial infarction; CHD, coronary heart disease; HADS, 
Hospital Anxiety and Depression Scale; ETS, environmental tobacco smoke.
29 
Table 1: Description of smoking stages of change 
Smoking stage of change Description 
Maintenance stage Having quit more than 6 months ago 
Action stage Having quit within the last 6 months 
Preparation stage Thinking of quitting within the next 30 days and having 
at least one 24-hour quit attempt in the past year 
Contemplation stage Thinking of quitting within the next 6 months or within 
the next 30 days without a 24-hour quit attempt in the 
past year 
Precontemplation stage Not thinking/being unsure of quitting 
30 
Table 2: Smoking stages of change [n (%)], total and by sex 
 Smoking stage of change 
 Precontemplation Contemplation Preparation Action Maintenance  
Men  551 
(25.4) 
366 
(16.9) 
179 
(8.3) 
113 
(5.2) 
957 
(44.2) 
Women 111 
(26.5) 
67 
(16.0) 
31 
(7.4) 
31 
(7.4) 
179 
(42.7) 
Total 662 
(25.6) 
443 
(16.8) 
210 
(8.1) 
144 
(5.6) 
1136 
(44.0) 
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Table 31: Separate associations of patient characteristics with advancement in smoking 
stages of change (N=2,585) 
  n Advancement in SSC 
   Odds ratio 95% CI p-value 
Age at event <50 years 601 1.00 Reference 0.280 
 50-59 years 1077 1.10 0.94-1.28  
 60-69 years 736 1.13 0.96-1.34  
 70-79 years 171 1.27 0.97-1.66  
Sex Men  2,166 1.00 Reference 0.725 
 Women 419 0.97 0.82-1.15  
Educational level Primary 619 1.00 Reference 0.004 
 Secondary 1,065 1.00 0.84-1.19  
 Intermediate 466 1.15 0.93-1.41  
 Higher 423 1.42 1.14-1.77  
Diagnostic group PCI 1,125 1.00 Reference 0.007 
 CABG 367 1.30 1.07-1.58  
 AMI 654 1.08 0.92-1.27  
 Ischemia 439 0.88 0.73-1.06  
Time since hospital 
admission 
per months  1.00 0.99-1.01 0.532 
32 
Recurrent CHD No 2,141 1.00 Reference 0.325 
 Yes 427 1.09 0.92-1.29  
Cardiac rehabilitation Not advised 1,456 1.00 Reference <0.001 
 Advised 231 1.31 1.03-1.65  
 Attended 864 1.50 1.28-1.76  
HADS anxiety <8 1,702 1.00 Reference 0.005 
 8-10 403 0.92 0.77-1.09  
 ≥11 364 0.74 0.62-0.88  
HADS depression <8 1,884 1.00 Reference <0.001 
 8-10 394 0.84 0.71-1.00  
 ≥11 206 0.61 0.49-0.76  
Smoking duration ≤26 years 641 1.00 Reference <0.001 
 27-34 years 642 0.79 0.69-0.98  
 35-40 years 677 0.60 0.51-0.72  
 >40 years 573 0.59 0.49-0.71  
ETS exposure No 1,204 1.00 Reference <0.001 
 Yes 1,354 0.50 0.44-0.57  
 
SSC, smoking stages of change; CI, confidence interval; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass graft; AMI, acute myocardial ischemia; 
33 
CHD, coronary heart disease; HADS: Hospital Anxiety and Depression Scale; ETS, 
environmental tobacco smoke. 
Odds ratios with 95% confidence intervals for the advancement in smoking stages of 
change from separate continuation ratio models with geographical region modelled as a 
random effect. 
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Table 42: Multivariable associations of patient characteristics with advancement in 
smoking stages of change (N=2,357) 
  n Advancement in SSC 
   Odds ratio 95% confidence interval 
Age at event <50 years 537 1.00 Reference 
 50-59 years 1,004 1.39 1.16-1.67 
 60-69 years 663 1.62 1.31-2.02 
 70-79 years 153 1.92 1.38-2.66 
Cardiac rehabilitation Not advised 1,342 1.00 Reference 
 Advised 218 1.22 0.95-1.56 
 Attended 797 1.37 1.16-1.63 
HADS depression <8 1,791 1.00 Reference 
 8-10 373 0.85 0.71-1.01 
 ≥11 193 0.60 0.48-0.76 
Smoking duration ≤26 years 600 1.00 Reference 
 27-34 years 600 0.70 0.58-0.85 
 35-40 years 637 0.48 0.40-0.59 
 >40 years 520 0.45 0.35-0.56 
ETS exposure No 1,119 1.00 Reference 
 Yes 1,238 0.51 0.44-0.58 
35 
HADS, Hospital Anxiety and Depression Scale; ETS, environmental tobacco smoke. 
Odds ratios with 95% confidence intervals for the advancement in smoking stages of 
change from a single continuation ratio model with geographical region modelled as a 
random effect and adjusted for age at event, cardiac rehabilitation, HADS depression, 
smoking duration and environmental tobacco smoke exposure. 
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